Writing this once so I can stop repeating it across threads. It is about mood and mental health, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
The mental-health dimension is under-measured in the trial literature and the reports here are consistent enough to take seriously. On the positive side: reduced anxiety around food, better self-image, more confidence. On the difficult side: grief for the years lost, identity disruption, relationships built around eating, and the loss of food as a coping mechanism with nothing put in its place. Rarer but real: anhedonia and emotional flatness. Regulators have started asking for validated patient-reported outcomes in this class; the existing data gap is not evidence of absence.
The condition it depends on
For anyone with an eating-disorder history this needs a clinician in the loop rather than a forum. The same drug can be therapeutic in binge-eating disorder and actively harmful in a restrictive disorder.
What I am not sure about
The bit I cannot resolve on my own is how people separated a drug effect from the ordinary consequences of a large deficit and disrupted sleep, because I cannot. Happy to be told the question itself is wrong.
Dr.PainCLE said:The mental-health dimension is under-measured in the trial literature and the reports here are consistent enough to take seriously.
Mood changes on mental health: I want to be transparent — I went through a rough patch emotionally around month 4. Not depression exactly, but a weird flatness. Food was my main coping mechanism and without that, I had to develop new ones.
Therapy has been essential. I'd strongly recommend anyone starting GLP-1 therapy also invest in mental health support. The physical transformation is only half the journey.
Dr.PainCLE said:The mental-health dimension is under-measured in the trial literature and the reports here are consistent enough to take seriously.
This is where I part company with the consensus forming above. I would be careful about how confidently the flatness reports get attributed. Rapid weight loss, a large deficit and disrupted sleep produce low mood on their own, and separating that from a drug effect is genuinely hard.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsVendorMark said:I would be careful about how confidently the flatness reports get attributed.
Recovering from an eating disorder and using mental health: this is a complex situation and I want to be transparent about it.
I have a history of binge eating disorder. My psychiatrist, therapist, and prescribing doctor all collaborate on my care. The GLP-1 agonist has actually been therapeutic — it removes the biological urgency of binge impulses without relying on restriction.
This is NOT appropriate for all ED patients. Anorexia, bulimia, and restrictive EDs require different approaches. But for BED specifically, the evidence and my personal experience are positive. Always involve your mental health team.
LipidDoc_ATL said:Mood changes on mental health: I want to be transparent — I went through a rough patch emotionally around month 4.
Same experience, arrived at from the opposite direction. Nothing to add that would improve it.